A 6-month, Multi-centre, Open Labelled, Non-randomized, Non-interventional, Safety Study of Liraglutide (Victoza) in Subjects With Type 2 Diabetes Mellitus in Korea
Phase of Trial: Phase IV
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 07 Jun 2017 Biomarkers information updated
- 17 Mar 2017 Status changed from recruiting to completed.
- 03 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Mar 2017.